United States: More Talk – No Action – From FDA On Off-Label "Communication"

Last Updated: September 6 2016
Article by James Beck

It's been over two years since the FDA – in March, 2014 Draft Guidelines and then in its June 2014 " grant" of an industry-submitted citizen's petition – promised to review its restrictions on so-called "off-label promotion" by regulated drug and medical device manufacturers.  We were skeptical at the time that all we would get is "still more agency bobbing and weaving."

Then two years with zilch – save more Agency First Amendment losses in off-label promotion cases.  Then industry gets sufficiently frustrated by FDA inaction on off-label communication issues that it starts to take matters into its own hands.

So, a month later, we finally hear from the FDA again.

Finally, some action?

Don't bet on it.

On August 31, 2016, a notice appeared in the Federal Register entitled "Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products; Public Hearing; Request for Comments."

Wonderful.  More talk, and the FDA kicks the can further down the road.  Once again the Agency refuses to recognizes the constitutional bind in which it finds itself.  Indeed, the term "First Amendment" doesn't appear anywhere – not even once – in the notice.  Nor does the FDA so much as utter the phrase "off-label."  Except for citations, the FDA uniformly uses the more pejorative term "unapproved."

If not the First Amendment, then, what do we have?

Well, the FDA asks for comments, meaning that regulated manufacturers get to spend more money paying their regulatory lawyers to repeat the same things one more time.  With respect to off-label communication:

FDA is interested in comment on the extent to which additional communications from firms about unapproved uses can provide access to information that is relevant, scientifically sound, responsibly presented, and provides as full an understanding as possible about the limitations of the available evidence, as well as comment on the extent to which health care professionals currently face impediments to accessing such information, whether from firms or from other sources.  FDA is interested in comment and information addressing whether and in what ways firms' communications of unapproved use information are distinct and perhaps provide unique benefits compared to other sources.

Notice – online version – at "Background."  OK, while we think this has been done to death, at least the FDA is asking pertinent questions.  To us it has never made any sense that, while any unregulated Tom, Diane or Harry can say whatever s/he wants in about off-label use public on the Internet, the entities with responsibility for researching their products and conducting adverse event reporting are muzzled.

The FDA makes a lot of references to "scientific" or "medical" information that is "relevant," "truthful," and "non-misleading."  We like that kind of information too, but we don't see how off-label use is so much different.  All information about all drugs and their uses – on- or off-label – should have these characteristics.  The FDA has decades of experience with these considerations already, in the context of indicated uses.  We don't see what more is necessary.  Granted, "[n]ot all communications of information about unapproved uses help support public health."  But "communications that emphasize a medical product's claimed benefits, while minimizing the limitations of the supporting evidence, or minimizing the product's known or potential adverse effects," are problematic whether or not the use appears on product labeling.  The FDA already has regulations (and extensive enforcement experience) regarding these concerns in the context of promotional activities generally.  Off-label use isn't any different in this respect.

The notice contains eight general topics which the Agency seeks comment, most of those broken into multiple subtopics, for a total of about 25.  Here they are in brief:

1. The public health impact of off-label communication by regulated persons:

  • Benefits and risks to recipients from increased communication about off-label use, given that the information be "preliminary or inconclusive."
  • Effects on prescribing, development, and research concerning new potential product uses.
  • Effects on incentives for patients to enroll in clinical trials, and for manufacturers to conduct them.
  • Could the impact be different for drugs, as opposed to biologics, medical devices, and other categories of regulated products?

2. Impact of the changing structure of the health care system, and its need for better data.

  • Data needs of payors and formulary committees that influence prescribing decisions.
  • Whether changes in the healthcare system preserve, enhance, or reduce incentives for manufacturers to seek FDA review of new uses.

3. The impact of increasing availability of off-label information through various sources on the incentives for manufacturers to engage in such communications, along with other factors (including financial) that affect these incentives.

4. Standards for off-label communication that would minimize the potential for the information to be misleading or otherwise harmful.

  • Processes that manufacturers use to determine what evaluate when off-label information is sufficiently reliable to communicate to those in the health care field.
  • Criteria that the FDA could use for making the same reliability determinations.
  • The extent and variability of health care professionals' understanding of the reliability of available information about off-label uses, and whether different audiences need different presentations of the same information.

" What off-label information is most important for health care professionals' ability to evaluate the reliability of off-label information, and whether this varies depending on the audience.

5. Standards for FDA determination whether off-label communications are truthful and not misleading, and what the content of these communications should be (again, we wonder why this is different than for on-label information).

  • Appropriate off-label disclaimers and whether these should vary by the means of communication.
  • How to determine when communications actually involve off-label uses, and how these determinations are made.
  • What kinds of risk, reliability, and regulatory information should accompany off-label communications.
  • How to present disclosures in off-label communication so that they are most effective, particularly as to scientific reliability.
  • When and under what conditions are off-label communications to the public – patients and other consumers – appropriate.

6. The extent to which non-public data should be disclosed if it forms the basis for an off-label communication.

7. Appropriate types of surveillance and monitoring for the FDA to conduct concerning off-label communications.

8. The FDA has stopped hiding its proposed changes to 21 C.F.R. §§201.128 801.4 that it slipped into a tobacco-related notice (80 Fed. Reg. 57756), and seeks input about:

  • Additional regulatory changes concerning communications, including whose concerning "false and misleading," "adequate directions for use," and how "labeling" is defined.
  • The advantages and disadvantages of alternative regulatory approaches to off-label communications with respect to the FDA's public health mission.

So here we go again.  A lot of these requests resemble those appearing in prior FDA notices.  For more details, we recommend the FDA Law Blog's discussion.

Information regarding attendance, registration, commenting, and presenting is also included in the notice.  Comments on the FDA's proposal will be accepted until January 9, 2017.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
James Beck
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.